Lyell Immunopharma (LYEL) Net Income towards Common Stockholders (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$103.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 19.91% year-over-year to -$103.2 million; the trailing twelve-month figure through Mar 2026 stood at -$465.5 million (up 50.67% YoY), and the FY2025 full-year result was -$286.5 million, up 60.08% from the prior year.
• Net Income towards Common Stockholders advanced to -$103.2 million in Q1 2026, from -$144.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$70.0 million in Q3 2023 to a low of -$561.1 million in Q4 2024.
• A 5-year average of -$160.1 million and a median of -$128.9 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders slumped 216.19% in 2022 and surged 74.21% in 2025, its largest moves.
• Tracing LYEL's Net Income towards Common Stockholders over 5 years: stood at -$192.5 million in 2022, then slumped by 59.38% to -$306.8 million in 2023, then sank by 82.85% to -$561.1 million in 2024, then surged by 74.21% to -$144.7 million in 2025, then rose by 28.67% to -$103.2 million in 2026.
• Business Quant data shows LYEL's Net Income towards Common Stockholders at -$103.2 million in Q1 2026, -$144.7 million in Q4 2025, and -$102.2 million in Q3 2025.